Clinical Research
Peer-reviewed evidence from JAMA, NEJM, and Health Affairs. Synthesized for care teams, not just academic readers. Because better evidence leads to better outcomes across the continuum.
Five Research Domains
The evidence categories most relevant to clinicians and operators across acute, post-acute, and home health settings.
Clinical Evidence & Trials
Phase 3 results, randomized controlled trials, and systematic reviews that change clinical practice. Curated for care teams managing complex patients across settings.
Patient Safety Research
Hospital-acquired infections, medication errors, fall prevention, and adverse event surveillance. Research that informs quality improvement and accreditation.
Care Transitions Science
Readmission research, discharge protocol studies, and cross-setting care coordination evidence. Directly relevant to discharge planners and post-acute operators.
Health Equity Studies
Disparities in access, outcomes, and care quality across demographic and geographic lines. Research that surfaces systemic gaps and informs policy and program design.
Technology Outcomes Research
Peer-reviewed evidence on AI diagnostic accuracy, EHR implementation outcomes, telehealth efficacy, and device performance in real-world clinical settings.
Click any domain to filter the live research feed below.
Research Funding Landscape
$198B+
Total U.S. Biomedical R&D
2024 estimate — industry, federal & academic
$47.1B
NIH Annual Budget
FY 2024 enacted · FY 2025 under review
$650M+
BRAIN Initiative (NIH)
FY 2024 allocation · 10-year program (2014–2034)
490K+
Registered Clinical Studies
ClinicalTrials.gov as of 2024
NIH Budget by Institute
FY 2024 enacted — $47.1B total across 27 institutes & centers
U.S. Research Funding Sources
Total ~$198B (2024 estimate) — industry, federal & academic
BRAIN Initiative
$650M+/yr NIH allocation (FY 2024) mapping neural circuits, 2014–2034. Parallel DoD and private sector investment exceeds $1B annually.
FY 2025 Budget Alert
Proposed executive-branch cuts of 30–40% to NIH and indirect cost caps are under legal challenge. Enacted FY 2025 appropriation not finalized as of mid-2025. Data above reflects FY 2024 baseline.
Sources: NIH Office of Budget (FY 2024 enacted) · PhRMA 2024 Annual Report (member R&D spend, 2023 data) · NSF National Patterns of R&D Resources · ClinicalTrials.gov registry (2024) · Federal figures reflect enacted appropriations. FY 2025 subject to legislative and executive action.
Doctor-Led. Evidence-Based.
NewsHX surfaces peer-reviewed research from the highest-impact journals in medicine. Articles link directly to source publications. We do not paraphrase or interpret study conclusions — summaries reflect the authors' published abstracts. Always read the full paper before applying findings in clinical practice.